Reuters logo
BRIEF-Immunomedics announces Sacituzumab Govitecan is active in patients
2016年6月6日 / 上午11点17分 / 1 年前

BRIEF-Immunomedics announces Sacituzumab Govitecan is active in patients

June 6 (Reuters) - Immunomedics Inc :

* Immunomedics announces Sacituzumab Govitecan (immu-132) is active in patients with previously-treated metastatic small-cell lung cancer

* Three of eight partial responders have been confirmed with follow-up computed tomography scan, to yield a confirmed response rate of 9 pct

* Immunomedics Inc says remaining five initial responders had progressive disease at confirmatory scan Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below